Akouos
AcquiredHealthy hearing available to all
Boston, United States · Founded 2016 · $162.5M raised
- Headquarters
- Boston, Massachusetts
- Employees
- 51–200
- Founded
- 2016
- Business Model
- B2B
- Website
- akouos.com
- Total Funding
- $162.5M
- Last Round
- $105.0M Series BMar 2020
- Rounds
- 3
- Acquisition Date
- Oct 2022
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 5 funding rounds and 4 investors for this company. The full record is or through the API.
About
Akouos is a precision genetic medicine company developing gene therapies to restore, improve, and preserve high-acuity physiologic hearing for people with disabling hearing loss. Focused on inner ear delivery and AAV gene therapy platforms, it was acquired by Eli Lilly. Targets genetic forms of hearing loss affecting 466 million worldwide.
Summary
Akouos is a Biotech company based in Boston, United States, founded in 2016. It has raised $162.5M in total across 3 rounds, most recently a $105.0M Series B round in Mar 2020. Investors include 5AM Ventures, New Enterprise Associates and Eli Lilly.
Funding & Exit History
Oct 2022
Sign up to see all 5 events
Funding: Seed through Series B. Amounts, valuations, and investors where available.
Investors
Similar Companies
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
Biotechnology company developing multi-cancer early detection blood tests using high-intensity ge...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/akouos"><img src="https://indexed.vc/api/badge/company/akouos" alt="Akouos on Indexed.vc" width="260" height="76" /></a>